http://hl7.org/fhir/uv/ebm/PublicationRecord/179629
type: PublicationRecord
resource definition: 1.0
resource definition: .0
node role: treeRoot
id:
  v: 179629
meta:
  version id:
    v: 23
  last updated:
    v: 2025-10-13T12:34:35.118Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation
    l: journal-article-citation
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: PublicationRecord 179629 version: 23; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: https://fevir.net/resources/PublicationRecord/179629 identifier: FEvIR Object Identifier/179629, https://pubmed.ncbi.nlm.nih.gov/23604530 title: 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. status: Active author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2013-08-01 lastReviewDate: 2021-11-22 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish statusDate activity: PubMed Pubstatus of Received period: ?? --> 2013-02-14 statusDate activity: PubMed Pubstatus of Accepted period: ?? --> 2013-04-08 statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2013-04-23 06:00:00+0000 statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2013-04-23 06:00:00+0000 statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2013-08-02 06:00:00+0000 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/23604530, https://doi.org/10.1007/s00280-013-2163-4 Titles - Type Language Text * Primary title English A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Abstracts - Type Text * Primary human use PURPOSE: Long-term hormonal ablation in pro…
contained: Practitioner
  id:
    v: contributor0
  name:
    family:
      v: Amato
    given:
      v: Robert
contained: Practitioner
  id:
    v: contributor1
  name:
    family:
      v: Stepankiw
    given:
      v: Mika
contained: Practitioner
  id:
    v: contributor2
  name:
    family:
      v: Gonzales
    given:
      v: Patricia
contained: ArtifactAssessment
  id:
    v: meshHeading0
  artifact: Reference
    l: #
    reference:
      v: #
    type:
      v: PublicationRecord
      l: PublicationRecord
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000230
    free to share:
      v: true
    component:
      classifier: Q000188
    component:
      classifier: Q000378
    component:
      classifier: Q000473
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000368
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000369
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000726
    free to share:
      v: true
    component:
      classifier: Q000008
    component:
      classifier: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000813
    free to share:
      v: true
    component:
      classifier: Q000008
    component:
      classifier: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D018931
    free to share:
      v: true
    component:
      classifier: Q000008
    component:
      classifier: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D000971
    free to share:
      v: true
    component:
      classifier: Q000008
    component:
      classifier: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D018572
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D006801
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D007610
    free to share:
      v: true
    component:
      classifier: Q000097
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D016729
    free to share:
      v: true
    component:
      classifier: Q000008
    component:
      classifier: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D008297
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D008875
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D060787
    free to share:
      v: true
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D009570
    free to share:
      v: true
    component:
      classifier: Q000008
    component:
      classifier: Q000627
  content:
    type:
      text:
        v: components (if present) include qualifier codings
    classifier: D017430
    free to share:
      v: true
    component:
      classifier: Q000097

v: mesh-heading

v: MeSH heading

v: D000230

v: Adenocarcinoma

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000188
display:
  v: drug therapy

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000378
display:
  v: metabolism

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000473
display:
  v: pathology

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D000368

v: Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000369

v: Aged, 80 and over

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D000726

v: Androgen Antagonists

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D000813

v: Anilides

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D018931

v: Antineoplastic Agents, Hormonal

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D000971

v: Antineoplastic Combined Chemotherapy Protocols

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49488
  display:
    v: Yes

v: mesh-heading

v: MeSH heading

v: D018572

v: Disease-Free Survival

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D006801

v: Humans

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D007610

v: Kallikreins

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000097
display:
  v: blood

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D016729

v: Leuprolide

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D008297

v: Male

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D008875

v: Middle Aged

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D060787

v: Neoplasm Grading

v: false

v: qualifier

v: is not a major topic

v: mesh-heading

v: MeSH heading

v: D009570

v: Nitriles

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000008
display:
  v: administration & dosage

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000627
display:
  v: therapeutic use

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

v: mesh-heading

v: MeSH heading

v: D017430

v: Prostate-Specific Antigen

v: false

v: qualifier

v: is not a major topic

v: qualifier

system:
  v: https://www.nlm.nih.gov/mesh
  l: mesh
code:
  v: Q000097
display:
  v: blood

text:
  v: is Major topic

coding:
  system:
    v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
    l: Thesaurus.owl
  code:
    v: C49487
  display:
    v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D011468
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D011468
    display:
      v: Prostatectomy
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D011471
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D011471
    display:
      v: Prostatic Neoplasms
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000188
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000188
      display:
        v: drug therapy
  component:
    type:
      text:
        v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000378
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000378
      display:
        v: metabolism
  component:
    type:
      text:
        v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000473
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000473
      display:
        v: pathology
  component:
    type:
      text:
        v: is Major topic

v: C49488

v: Yes

v: C49487

v: No

v: C49487

v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D011878
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D011878
    display:
      v: Radiotherapy
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D014105
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D014105
    display:
      v: Tosyl Compounds
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000008
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000008
      display:
        v: administration & dosage
  component:
    type:
      text:
        v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier: Q000627
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000627
      display:
        v: therapeutic use
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

v: C49487

v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier: D017211
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017211
    display:
      v: Treatment Failure
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

url:
  v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
  l: artifact-publication-status
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
      l: cited-artifact-status-type
    code:
      v: active
    display:
      v: Active

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 179629
assigner:
  display:
    v: Computable Publishing LLC

system:
  v: https://pubmed.ncbi.nlm.nih.gov
  l: pubmed.ncbi.nlm.nih.gov
value:
  v: 23604530

v: 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

v: active

name:
  v: Computable Publishing®: MEDLINE-to-FEvIR Converter

v: Computable Publishing LLC

telecom:
  system:
    v: email

v: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-classification-type
    l: citation-classification-type
  code:
    v: fevir-platform-use
  display:
    v: FEvIR Platform Use
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: medline-base
    display:
      v: Medline Base
    user selected:
      v: false

v: 2013-08-01

v: 2021-11-22

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: citation-source
    display:
      v: Citation Source
classifier:
  text:
    v: MEDLINE

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: medline-owner
    display:
      v: MEDLINE Citation Owner
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
      l: owner value
    code:
      v: NLM
    display:
      v: National Library of Medicine, Index Section
    user selected:
      v: false

coding:
  system:
    v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
    l: publicationrecord-status-type
  code:
    v: medline-medline
  display:
    v: Medline Citation Status of Medline

coding:
  system:
    v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
    l: publicationrecord-status-type
  code:
    v: pubmed-publication-status-ppublish
  display:
    v: PubMed PublicationStatus of ppublish

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-received
    display:
      v: PubMed Pubstatus of Received
period:
  end:
    v: 2013-02-14

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-accepted
    display:
      v: PubMed Pubstatus of Accepted
period:
  end:
    v: 2013-04-08

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-entrez
    display:
      v: PubMed Pubstatus of Entrez
period:
  end:
    v: 2013-04-23T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-pubmed
    display:
      v: PubMed Pubstatus of Pubmed
period:
  end:
    v: 2013-04-23T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/uv/ebm-incubator/CodeSystem/publicationrecord-status-type
      l: publicationrecord-status-type
    code:
      v: pubmed-pubstatus-medline
    display:
      v: PubMed Pubstatus of Medline
period:
  end:
    v: 2013-08-02T06:00:00.000Z

identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 23604530
identifier:
  system:
    v: https://doi.org
    l: doi.org
  value:
    v: 10.1007/s00280-013-2163-4
title:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/title-type
        l: title-type
      code:
        v: primary
      display:
        v: Primary title
  language:
    v: en
  text:
    v: A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
abstract:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type
        l: cited-artifact-abstract-type
      code:
        v: primary-human-use
      display:
        v: Primary human use
  text:
    v: **PURPOSE:** Long-term hormonal ablation in prostate cancer is associated with decreased overall health and quality of life. Few reports emphasized the role of chemotherapy in the management of early stage prostate cancer. This study analyzed the safety and efficacy of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for patients identified as local failures or not eligible for prostatectomy or radiation therapy due to advanced disease presentation. **METHODS:** Enrolled patients received ADT in the form of leuprolide every 12 weeks for 24 months with bicalutamide initiating after the completion of chemotherapy. Chemotherapy consisted of ketoconazole and doxorubicin for weeks 1, 3, and 5 and estramustine and docetaxel and for weeks 2, 4 and 6. During weeks 7 and 8, no treatment was received. **RESULTS:** Forty-six patients were enrolled, and forty-five patients were evaluable. Median progression-free survival (PFS) was 23.4 months. Median overall survival (OS) was 53.7 months. Out of 45 patients with measurable disease, 22 patients had an objective response: 9 patients achieved a complete response; 2 patients achieved a partial response; 10 patients achieved stable disease. Frequent grade 3 adverse events included elevated ALT (17 %), hypokalemia (13 %), and hypophosphatemia (13 %). Grade 4 adverse events were rare and included low bicarbonate (2 %), hypokalemia (2 %), leukocytopenia (2 %), and neutropenia (2 %). **CONCLUSIONS:** The treatment demonstrated clinical benefit in all patient subsets with minimal reversible treatment-related adverse events. Subgroup analysis suggests that having prior local therapy resulted in greater PFS and OS.
publication form:
  published in:
    identifier:
      system:
        v: https://portal.issn.org
        l: portal.issn.org
      value:
        v: 1432-0843
    identifier:
      system:
        v: https://www.issn.org/services/online-services/access-to-the-ltwa/
        l: access-to-the-ltwa
      value:
        v: Cancer Chemother Pharmacol
    identifier:
      system:
        v: https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/
        l: the-issn-l-for-publications-on-multiple-media
      value:
        v: 0344-5704
    identifier:
      system:
        v: https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html
        l: contructitleabbre.html
      value:
        v: Cancer Chemother Pharmacol
    identifier:
      system:
        v: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
        l: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
      value:
        v: 7806519
    title:
      v: Cancer chemotherapy and pharmacology
    publisher location:
      v: Germany
  cited medium:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-medium
        l: cited-medium
      code:
        v: internet
      display:
        v: Internet
  volume:
    v: 71
  issue:
    v: 6
  article date:
    v: 2013-06
  page string:
    v: 1629-34
publication form:
  cited medium:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-medium
        l: cited-medium
      code:
        v: internet-without-issue
      display:
        v: Internet without issue
  article date:
    v: 2013-04-21
web location:
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
        l: artifact-url-classifier
      code:
        v: abstract
      display:
        v: Abstract
  url:
    v: https://pubmed.ncbi.nlm.nih.gov/23604530/
    l: https://pubmed.ncbi.nlm.nih.gov/23604530/
web location:
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
        l: artifact-url-classifier
      code:
        v: doi-based
      display:
        v: DOI Based
  url:
    v: https://doi.org/10.1007/s00280-013-2163-4
    l: s00280-013-2163-4
classification:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: publishing-model
      display:
        v: Publishing Model
      user selected:
        v: false
  classifier:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: Print-Electronic
      display:
        v: Print Electronic
      user selected:
        v: false
classification:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: chemical
      display:
        v: Chemical
      user selected:
        v: false
  classifier: D000726
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D000726
      display:
        v: Androgen Antagonists
      user selected:
        v: false
  classifier: D000813
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D000813
      display:
        v: Anilides
      user selected:
        v: false
  classifier: D018931
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D018931
      display:
        v: Antineoplastic Agents, Hormonal
      user selected:
        v: false
  classifier: D009570
    coding:
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D009570
  classifier: D014105
  classifier: C053541
  classifier: C549870
  classifier: D007610
  classifier: D017430
  classifier: D016729

v: D020492

v: Periodical

system:
  v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn
  l: issn
code:
  v: Electronic
display:
  v: Electronic

v: Electronic ISSN Type

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: ISOAbbreviation

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: ISSN Linking

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: Medline Title Abbreviation

system:
  v: http://terminology.hl7.org/CodeSystem/v2-0203
  l: v2-0203
code:
  v: XX
display:
  v: Organization identifier

v: NLM Unique ID

v: Nitriles

v: false

D014105
coding:
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: D014105
  display:
    v: Tosyl Compounds
  user selected:
    v: false

C053541
coding:
  system:
    v: https://www.cas.org/support/documentation/chemical-substances
    l: chemical-substances
  code:
    v: A0Z3NAU9DP
  user selected:
    v: false
coding:
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: C053541
  display:
    v: bicalutamide
  user selected:
    v: false

C549870
coding:
  system:
    v: https://www.cas.org/support/documentation/chemical-substances
    l: chemical-substances
  code:
    v: EC 3.4.21.-
  user selected:
    v: false
coding:
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: C549870
  display:
    v: KLK3 protein, human
  user selected:
    v: false

D007610
coding:
  system:
    v: https://www.cas.org/support/documentation/chemical-substances
    l: chemical-substances
  code:
    v: EC 3.4.21.-
  user selected:
    v: false
coding:
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: D007610
  display:
    v: Kallikreins
  user selected:
    v: false

D017430
coding:
  system:
    v: https://www.cas.org/support/documentation/chemical-substances
    l: chemical-substances
  code:
    v: EC 3.4.21.77
  user selected:
    v: false
coding:
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: D017430
  display:
    v: Prostate-Specific Antigen
  user selected:
    v: false

D016729
coding:
  system:
    v: https://www.cas.org/support/documentation/chemical-substances
    l: chemical-substances
  code:
    v: EFY6W0M8TG
  user selected:
    v: false
coding:
  system:
    v: https://www.nlm.nih.gov/mesh
    l: mesh
  code:
    v: D016729
  display:
    v: Leuprolide
  user selected:
    v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
artifact assessment:
  l: meshHeading0
  reference:
    v: #meshHeading0
  type:
    v: ArtifactAssessment
    l: ArtifactAssessment

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publication-type
    display:
      v: Publication type
classifier: D017427
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017427
    display:
      v: Clinical Trial, Phase II
    user selected:
      v: false
classifier: D016428
  coding:
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: knowledge-artifact-type
    display:
      v: Knowledge Artifact Type
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
artifact assessment:
  display:
    v: Classifier added by Computable Publishing LLC

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: citation-subset
    display:
      v: Citation subset
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
      l: citationsubset
    code:
      v: IM
    display:
      v: IM
    user selected:
      v: false

complete:
  v: true
entry:
  contributor:
    l: contributor0
    reference:
      v: #contributor0
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Amato R
  forename initials:
    v: R
  affiliation:
    display:
      v: Division of Oncology, Department of Internal Medicine, University of Texas Health Science Center at Houston (Medical School)/Memorial Hermann Cancer Center, 6410 Fannin St., Suite 830, Houston, TX 77030, USA. robert.amato@uth.tmc.edu
entry:
  contributor:
    l: contributor1
    reference:
      v: #contributor1
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Stepankiw M
  forename initials:
    v: M
entry:
  contributor:
    l: contributor2
    reference:
      v: #contributor2
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Gonzales P
  forename initials:
    v: P